Stock Scorecard



Stock Summary for Twist Bioscience Corp (TWST) - $35.89 as of 6/19/2025 8:46:59 PM EST

Total Score

9 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for TWST

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for TWST

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for TWST

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for TWST

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for TWST (40 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for TWST

Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could Benefit - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , Illumina ( NASDAQ:ILMN ) 5/26/2025 8:25:00 AM
Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation - Archer Aviation ( NYSE:ACHR ) , ARK Fintech Innovation ETF ( BATS:ARKF ) 5/14/2025 1:32:00 AM
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots - Amgen ( NASDAQ:AMGN ) , Bristol-Myers Squibb ( NYSE:BMY ) 5/12/2025 11:23:00 AM
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Quest Diagnostics ( NYSE:DGX ) , Castle Biosciences ( NASDAQ:CSTL ) 5/6/2025 1:13:00 PM
Twist Bioscience ( TWST ) Reports Q2 Loss, Tops Revenue Estimates 5/5/2025 12:25:00 PM
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics 3/31/2025 1:03:00 PM
Promising Genomics & Synthetic Biology Stocks to Consider in 2025 3/28/2025 1:39:00 PM
Twist Bioscience ( TWST ) Moves 6.6% Higher: Will This Strength Last? 3/12/2025 4:12:00 PM
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday - Archer Aviation ( NYSE:ACHR ) , Accolade ( NASDAQ:ACCD ) 3/1/2025 10:06:00 AM
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday - ARK Fintech Innovation ETF ( ARCA:ARKF ) , ARK Genomic Revolution ETF ( BATS:ARKG ) 2/15/2025 10:24:00 AM

Financial Details for TWST

Company Overview

Ticker TWST
Company Name Twist Bioscience Corp
Country USA
Description Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 35.89
Price 4 Years Ago 77.39
Last Day Price Updated 6/19/2025 8:46:59 PM EST
Last Day Volume 1,072,687
Average Daily Volume 1,169,949
52-Week High 60.90
52-Week Low 27.12
Last Price to 52 Week Low 32.34%

Valuation Measures

Trailing PE N/A
Industry PE 60.81
Sector PE 40.43
5-Year Average PE -18.92
Free Cash Flow Ratio 10.23
Industry Free Cash Flow Ratio 19.08
Sector Free Cash Flow Ratio 31.51
Current Ratio Most Recent Quarter 4.51
Total Cash Per Share 3.51
Book Value Per Share Most Recent Quarter 7.35
Price to Book Ratio 4.89
Industry Price to Book Ratio 18.89
Sector Price to Book Ratio 30.07
Price to Sales Ratio Twelve Trailing Months 6.18
Industry Price to Sales Ratio Twelve Trailing Months 46.69
Sector Price to Sales Ratio Twelve Trailing Months 34.41
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 59,916,000
Market Capitalization 2,150,385,240
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -2.01%
Reported EPS 12 Trailing Months -3.44
Reported EPS Past Year -1.19
Reported EPS Prior Year -3.60
Net Income Twelve Trailing Months -191,148,000
Net Income Past Year -208,726,000
Net Income Prior Year -204,618,000
Quarterly Revenue Growth YOY 23.20%
5-Year Revenue Growth 41.91%
Operating Margin Twelve Trailing Months -44.80%

Balance Sheet

Total Cash Most Recent Quarter 210,437,000
Total Cash Past Year 226,316,000
Total Cash Prior Year 286,470,000
Net Cash Position Most Recent Quarter 210,437,000
Net Cash Position Past Year 226,316,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 1,662,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 472,689,000
Total Stockholder Equity Prior Year 623,432,000
Total Stockholder Equity Most Recent Quarter 440,108,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -65,491,000
Free Cash Flow Per Share Twelve Trailing Months -1.09
Free Cash Flow Past Year -69,170,000
Free Cash Flow Prior Year -170,253,000

Options

Put/Call Ratio 1.19
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.20
MACD Signal -1.12
20-Day Bollinger Lower Band 25.21
20-Day Bollinger Middle Band 38.54
20-Day Bollinger Upper Band 51.86
Beta 2.37
RSI 58.44
50-Day SMA 43.36
150-Day SMA 33.27
200-Day SMA 42.26

System

Modified 6/19/2025 12:15:44 PM EST